# ARTBIO Closes $132M Series B to Advance Alpha Radioligand Therapy for Prostate Cancer

> financing · REPORTED · 2025-07-29

ARTBIO, a clinical-stage radiopharmaceutical company, closed a $132 million Series B co-led by Sofinnova Investments and B Capital, with Qatar Investment Authority and Alexandria Venture Investments joining, to advance its lead alpha radioligand therapy AB001 in metastatic castration-resistant prostate cancer through Phase 2 and expand its proprietary distributed manufacturing supply chain.

- Company: ARTBIO
- Sector: oncology
- Primary source: https://www.prnewswire.com/news-releases/artbio-announces-132-million-series-b-financing-to-advance-pipeline-of-alpha-radioligand-therapies-and-expand-manufacturing-and-supply-chain-infrastructure-302515362.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.